PROXIMAGEN LLC has a total of 80 patent applications. It increased the IP activity by 350.0%. Its first patent ever was published in 2011. It filed its patents most often in United Kingdom, United States and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are BIOPROJET PHARMA, KRONOS BIO INC and PULMAGEN THERAPEUTICS INFLAMMATION LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 27 | |
#2 | United States | 11 | |
#3 | Australia | 10 | |
#4 | EPO (European Patent Office) | 8 | |
#5 | Hungary | 5 | |
#6 | Israel | 3 | |
#7 | Singapore | 3 | |
#8 | Brazil | 2 | |
#9 | Canada | 2 | |
#10 | Republic of Korea | 2 | |
#11 | Mexico | 2 | |
#12 | WIPO (World Intellectual Property Organization) | 2 | |
#13 | EAPO (Eurasian Patent Organization) | 1 | |
#14 | Hong Kong | 1 | |
#15 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Acyclic or carbocyclic compounds | |
#5 | Organic chemistry methods | |
#6 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Patient Lee | 26 |
#2 | Simpson Iain | 18 |
#3 | Savory Edward | 17 |
#4 | Richardson Peter | 13 |
#5 | Espensen Max | 13 |
#6 | Evans David | 11 |
#7 | Pullman William | 7 |
#8 | Walling Jacqueline Mary | 5 |
#9 | Brown Giles | 5 |
#10 | Festuccia Claudio | 5 |
Publication | Filing date | Title |
---|---|---|
GB202101620D0 | New compounds | |
GB202101607D0 | New compounds | |
GB202101616D0 | New compounds | |
GB202101617D0 | New compounds | |
GB202101614D0 | New compounds | |
GB202101609D0 | New compounds | |
GB202101600D0 | New compounds | |
GB202101621D0 | New compounds | |
GB202101602D0 | New compounds | |
WO2020222190A1 | Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide | |
WO2020222189A1 | Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide | |
GB202001646D0 | New compounds | |
GB202001643D0 | New compounds | |
GB202001639D0 | New compounds | |
GB202001648D0 | New compounds | |
GB202001642D0 | New compounds | |
GB202001640D0 | New compounds | |
GB202001649D0 | New compounds | |
GB202001644D0 | New compounds | |
GB202001645D0 | New compounds |